Manufactures ayurvedic and nutraceutical products from a facility at Xcelon Industrial Park in Ahmedabad, Gujarat, and also offers CDMO (contract development and manufacturing) services to other companies. FY26 revenue was Rs. 33.60 crore, up 110% from Rs. 16.00 crore in FY25, with growth driven by demand for its nutraceutical and ayurvedic products, an expanded customer base, a richer product mix and higher CDMO contribution. Profit after tax was Rs. 5.07 crore on EBITDA of Rs. 7.01 crore. The business runs on a very raw-material-heavy cost structure: materials accounted for 73.6% of FY26 revenue, against just 3.2% for employees and 4.6% for other operating expenses. It follows an export-led strategy, winning a Global Export Excellence Award in Ayurvedic and Nutraceutical Manufacturing, and is working on product registrations and market approvals in international markets. The company raised Rs. 24.77 crore through an IPO and listed on the BSE SME platform in February 2026, using Rs. 7.04 crore of the proceeds on machinery, Rs. 5.24 crore on working capital, Rs. 3.69 crore on corporate purposes and Rs. 3.33 crore on IPO expenses, with Rs. 6.55 crore still unutilised. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Nutraceutical products, Ayurvedic products, CDMO services. Small, manufacturing-led ayurvedic and nutraceutical business with contract manufacturing (CDMO) work and an export focus.
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 34 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 9.35 |
| ROE % · ROCE % | — · 17.2 |
| Debt / equity (x) | — |
| Cash from operations | (24) |
| Capex | (0) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 20 |
| Profit before tax | 3 |
| Net profit | — |
| EPS (₹) | 4.53 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 10 Sept 2026 · Newspaper ad on completion of Postal Ballot Notice dispatch | compliance | minimal | — | — |
| 9 Sept 2026 · Postal ballot: MOA change, borrowing limit raised to Rs 500 crore, related party approvals | board shareholder meetings | low | — | — |
| 2 Sept 2026 · Board approves MoA changes, higher borrowing and investment limits | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Board approves broader business scope and higher borrowing limits | general | medium | — | — |
| 1 Sept 2026 · Board approves MOA overhaul and higher borrowing powers | general | medium | — | — |
| 27 Aug 2026 · 5th AGM: All 10 Resolutions Passed with 100% Approval | board shareholder meetings | low | — | — |
| 27 Aug 2026 · 5th AGM held on 27 Aug 2026 - key resolutions passed | board shareholder meetings | low | — | — |
| 6 Aug 2026 · AGM notice and annual report link sent to shareholders | compliance | minimal | — | — |
| 5 Aug 2026 · Newspaper notice for 5th AGM and e-voting procedure | compliance | minimal | — | — |
| 4 Aug 2026 · Accretion Nutraveda 5th AGM notice on 27 Aug 2026 via video conferencing | board shareholder meetings | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 59.6 | 28.9 | 138 of 169 | 19% |
| ROCE | 15.8 | 10.8 | 57 of 183 | 69% |
| Market cap | 195 | 839 | 117 of 182 | 36% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
